LEGEND BIOTECH CORPORA

Legend Biotech Reports Third Quarter 2024 Results and Recent Highlights

12 Nov 2024 07:00:01 By Nasdaq GlobeNewswire

Legend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

07 Nov 2024 07:30:00 By Nasdaq GlobeNewswire

Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma

05 Nov 2024 09:10:00 By Nasdaq GlobeNewswire

Legend Biotech Appoints Alan Bash as President of CARVYKTI®

04 Nov 2024 07:30:00 By Nasdaq GlobeNewswire

Legend Biotech to Host Investor Conference Call on Third Quarter 2024 Results

24 Oct 2024 08:00:01 By Nasdaq GlobeNewswire

Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia

03 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second Line

27 Sep 2024 16:35:00 By Nasdaq GlobeNewswire

Legend Biotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

20 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

Legend Biotech Reports Second Quarter 2024 Results and Recent Highlights

09 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Legend Biotech Appoints Peter Salovey, Ph.D., to its Board of Directors

08 Aug 2024 16:05:00 By Nasdaq GlobeNewswire

Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2024

26 Jul 2024 07:00:00 By Nasdaq GlobeNewswire

Legend Biotech to Host Investor Conference Call on Second Quarter 2024 Results

10 Jul 2024 08:00:00 By Nasdaq GlobeNewswire

Legend Biotech Announces Positive Overall Survival Results of Landmark Phase 3 CARTITUDE-4 Trial in Multiple Myeloma

02 Jul 2024 08:00:00 By Nasdaq GlobeNewswire